Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Baxter
US Army
Fish and Richardson
UBS
Dow
Chinese Patent Office
Johnson and Johnson
Federal Trade Commission
McKinsey

Generated: August 20, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 9,408,893 protect, and when does it expire?


Patent ► Subscribe protects ADLYXIN and is included in one NDA.

This patent has sixteen patent family members in nineteen countries.

Summary for Patent: ► Subscribe

Title:Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
Abstract: The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.
Inventor(s): Niemoeller; Elisabeth (Frankfurt am Main, DE), Muehlen-Bartmer; Isabel (Frankfurt am Main, DE), Silvestre; Louise (Paris, FR), Boka; Gabor (Paris, FR), Miossec; Patrick (Paris, FR)
Assignee: Sanofi-Aventis Deutschland GMBH (Frankfurt am Main, DE)
Application Number:13/595,590
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sanofi-aventis Us
ADLYXIN
lixisenatide
SOLUTION;SUBCUTANEOUS208471-001Jul 27, 2016RXYesYes► Subscribe► Subscribe
Sanofi-aventis Us
ADLYXIN
lixisenatide
SOLUTION;SUBCUTANEOUS208471-002Jul 27, 2016RXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
11179149Aug 29, 2011

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan2014527063► Subscribe
HungaryE027989► Subscribe
CroatiaP20151068► Subscribe
Hong Kong1196267► Subscribe
Spain2550357► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Cipla
Healthtrust
Boehringer Ingelheim
Covington
Chubb
US Army
Novartis
Johnson and Johnson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot